

# City of Hope Comprehensive Cancer Center

June 25, 2017

Steven T. Rosen, M.D.

Provost and Chief Scientific Officer

Director, Comprehensive Cancer Center and

Beckman Research Institute

Irell & Manella Cancer Center Director's Distinguished Chair




# City of Hope

1913



2014





# CITY OF HOPE LOCATIONS



[cityofhope.org/locations](http://cityofhope.org/locations)

LEGEND		
<b>1. CITY OF HOPE MAIN CAMPUS</b>	1500 Duarte Road, Duarte, CA 91010 800-826-HOPE	
<b>2. ANTELOPE VALLEY</b>	44151 15th St. West, Lancaster, CA 93534 877-828-3627	
<b>3. ARCADIA</b>	301 W. Huntington Dr., Ste. 400, Arcadia, CA 91007 626-218-9840	
<b>4. ARCADIA RADIATION ONCOLOGY</b>	301 W. Huntington Dr., Arcadia, CA 91007 626-574-3657	
<b>5. CORONA</b>	1280 Corona Pointe Ct., Ste. 112, Corona, CA 92879 951-898-2828	
<b>6. GLENDORA</b>	412 West Carroll Ave., Suite 200 Glendora, CA 91741 626-914-3921	
<b>7. MISSION HILLS</b>	15031 Rinaldi Street, Mission Hills, CA 91345 818-660-4700	
<b>8. PALM SPRINGS</b>	1180 N. Indian Canyon Dr., Ste. #E-218, Palm Springs, CA 92262 760-416-4832	
<b>9. PASADENA</b>	630 S. Raymond, #220, Pasadena, CA 91105 626-396-2900	
<b>10. RANCHO CUCAMONGA</b>	8283 Grove Ave., Ste. 207, Rancho Cucamonga, CA 91730 909-949-2242	
<b>11. SANTA CLARITA</b>	26357 McBean Pkwy., Ste. 150, Santa Clarita, CA 91355 661-799-1999	
<b>12. SIMI VALLEY</b>	1157 Swallow Lane, Simi Valley, CA 93065 805-527-2770	
<b>13. SOUTH PASADENA</b>	209 Fair Oaks, South Pasadena, CA 91030 877-998-7546	
<b>14. WEST COVINA</b>	1250 S. Sunset Ave., Ste. 303, West Covina, CA 91790 626-856-5858	



# CTCL Represents a Fraction of All NHL Diagnosis

**CTCL is ~3 % of all NHL diagnoses<sup>1</sup>**



Figures derived from Criscione et al., *Arch Dermatol.* 2007

**~16,000-20,000 patients with MF in the US<sup>3</sup>**

**~1,500-3,000 new MF cases diagnosed each year<sup>4,5</sup>**

1. Morton LM et al. *Blood.* 2007;110:695-708. 2. Criscione VD et al. *Arch Dermatol.* 2007;143:854-859. 3. Cutaneous Lymphoma Foundation. [http://www.clfoundation.org/about\\_cutaneous\\_lymphoma/CL\\_fast\\_facts.htm](http://www.clfoundation.org/about_cutaneous_lymphoma/CL_fast_facts.htm). Accessed September 21, 2011. 4. The Leukemia & Lymphoma Society Website. [http://www.leukemialymphoma.org/attachments/National/br\\_1163608564.pdf](http://www.leukemialymphoma.org/attachments/National/br_1163608564.pdf). Accessed September 21, 2011. 5. Cutaneous Lymphoma Foundation. [http://www.clfoundation.org/publications/CLF\\_SS\\_Fast\\_Facts.pdf](http://www.clfoundation.org/publications/CLF_SS_Fast_Facts.pdf). Accessed September 21, 2011.

# CTCL in WHO 2008 Lymphoma Classifications

## Extranodal-Cutaneous<sup>1</sup>

- Mycosis fungoides
- Sézary syndrome
- Primary cutaneous CD30+ lymphoproliferative disorders
  - Primary cutaneous anaplastic large cell lymphoma
  - Lymphomatoid papulosis
- Subcutaneous panniculitis-like T-cell lymphoma
- Primary cutaneous  $\gamma\delta$  T-cell lymphoma
- Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma
- Primary cutaneous small/medium CD4+ T-cell lymphoma

**Mycosis fungoides (60%) and Sézary syndrome (5%) are the most common subtypes of CTCL<sup>2</sup>**

# CTCL Clinical Manifestations Vary Depending on Stage of Disease

## Typical early-stage CTCL clinical manifestations:

- Antecedent skin lesions (typically erythematous patches)
- Plaque lesions
- Sézary syndrome patients may have:
  - Generalized desquamative erythroderma
  - Pruritis
  - Circulating malignant cells

## Typical later-stage CTCL clinical manifestations:

- Progression from limited to generalized patches, plaques, tumors and nodal or visceral involvement
- Tumor lesions, frequently associated with previous patches or plaques, anywhere on the body, which may become ulcerative
- Sézary syndrome patients may have alopecia, ectropion, leonine facies, hyperkeratosis, nail dystrophy, fissuring of the palms and soles, severe pruritis, or cutaneous pain

# CTCL Disease Stage Influences Treatment Options





Chart derived from NCCN Clinical Practice Guidelines in Oncology. v.4.2011.

# Mycosis Fungoides/Sézary Syndrome Treatment Algorithm





# Treatment Trials

#16065 Topical Naloxone Hydrochloride Lotion for the relief of Pruritus

#15157 Valchlor QoL

#15122 Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation (Phase III)

#16273 Intratumoral Injections of TTI-621 (Phase I) (anti-Cd407)

#15192 Bcl-2 Expression

#16221 Durvalumab +/- Lenalidomide (Phase I/II)

#15428 Safety, Efficacy of RP6530, Dual PI3K Deta/Gamma Inhibitor

#15270 Safety, Tolerability, and Pharmacokinetics of MRG-106 (Phase I)

#15186 T-Cell Exhaustion in Cutaneous Lymphoma

#15126 Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Vs. Vorinostat



City of  
Hope